Decitabine Tăng Cường Sự Di Chuyển và Chức Năng của Lymphocyte và Hợp Tác Với Sự Chặn CTLA-4 Trong Mô Hình Ung Thư Buồng Trứng Ở Chuột
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nishikawa, 2014, Regulatory T cells in cancer immunotherapy, Curr Opin Immunol, 27, 1, 10.1016/j.coi.2013.12.005
Simpson, 2013, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J Exp Med, 210, 1695, 10.1084/jem.20130579
Eagar, 2004, CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance, J Immunol, 172, 7442, 10.4049/jimmunol.172.12.7442
Pentcheva-Hoang, 2014, Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility, Cancer Immunol Res, 2, 970, 10.1158/2326-6066.CIR-14-0104
Liu, 2009, Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells, Cancer Immunol Immunother, 58, 687, 10.1007/s00262-008-0591-5
Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358
Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694
Rodríguez-Paredes, 2011, Cancer epigenetics reaches mainstream oncology, Nat Med, 17, 330, 10.1038/nm.2305
Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027
Paz, 2003, A systematic profile of DNA methylation in human cancer cell lines, Cancer Res, 63, 1114
Tsai, 2012, Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells, Cancer Cell, 21, 430, 10.1016/j.ccr.2011.12.029
Wrangle, 2013, Alterations of immune response of non-small cell lung cancer with azacytidine, Oncotarget, 4, 2067, 10.18632/oncotarget.1542
Li, 2014, Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers, Oncotarget, 5, 587, 10.18632/oncotarget.1782
Sabado, 2015, Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma, Cancer Immunol Res, 3, 278, 10.1158/2326-6066.CIR-14-0202
Adair, 2009, Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex encoded molecules, Cancer Immunol Immunother, 58, 589, 10.1007/s00262-008-0582-6
Dubovsky, 2009, Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen, Clin Cancer Res, 15, 3406, 10.1158/1078-0432.CCR-08-2099
Woloszynska-Read, 2008, Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer, Clin Cancer Res, 14, 3283, 10.1158/1078-0432.CCR-07-5279
Xing, 2006, A mouse model for the molecular characterization of brca1-associated ovarian carcinoma, Cancer Res, 66, 8949, 10.1158/0008-5472.CAN-06-1495
Placke, 2010, Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation, Clin Dev Immunol, 2010, 239083, 10.1155/2010/239083
Koizumi, 2007, Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response, Cancer Sci, 98, 1652, 10.1111/j.1349-7006.2007.00606.x
Sato, 2005, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proc Natl Acad Sci U S A, 102, 18538, 10.1073/pnas.0509182102
Stojanovic, 2014, CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells, J Immunol, 192, 4184, 10.4049/jimmunol.1302091
Li, 2015, Decitabine: a promising epi-immunotherapeutic agent in solid tumors, Expert Rev Clin Immunol, 11, 363, 10.1586/1744666X.2015.1002397
Cruz, 2011, Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4, Clin Cancer Res, 17, 7058, 10.1158/1078-0432.CCR-11-1873
Odunsi, 2014, Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer, Cancer Immunol Res, 2, 37, 10.1158/2326-6066.CIR-13-0126
Ottaviani, 2006, CD56brightCD16(−) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation, Eur J Immunol, 36, 118, 10.1002/eji.200535243
Muenchmeier, 2013, A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy, PLoS ONE, 8, e72749, 10.1371/journal.pone.0072749
Harlin, 2009, Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment, Cancer Res, 69, 3077, 10.1158/0008-5472.CAN-08-2281
Kunz, 1999, Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma, J Pathol, 189, 552, 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I
Burckhart, 2010, Tumor-specific crosslinking of GITR as costimulation for immunotherapy, J Immunother, 33, 925, 10.1097/CJI.0b013e3181f3cc87
Schmiedel, 2013, Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia, Mol Ther, 21, 877, 10.1038/mt.2013.11
Pedroza-Gonzalez, 2013, T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment, Oncoimmunology, 2, e22450, 10.4161/onci.22450
Schmiedel, 2011, Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation, Int J Cancer, 128, 2911, 10.1002/ijc.25635
Pal, 2005, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases, Cancer, 104, 2807, 10.1002/cncr.21536
Obermajer, 2011, PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment, Cancer Res, 71, 7463, 10.1158/0008-5472.CAN-11-2449
Triozzi, 2012, Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice, Cancer Immunol Immunother, 61, 1441, 10.1007/s00262-012-1204-x
Wiltrout, 1982, Variation in selectivity of tumor cell cytolysis by murine macrophages, macrophage-like cell lines and NK cells, Int J Cancer, 30, 335, 10.1002/ijc.2910300313
Weiner, 2010, Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nat Rev Immunol, 10, 317, 10.1038/nri2744
Goyne, 2012, The case for HER2/neu as a therapeutic target for gynecologic malignancies, Immunotherapy, 4, 781, 10.2217/imt.12.71
Kost, 1999, Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors, Gynecol Oncol, 72, 392, 10.1006/gyno.1998.5257
Wang, 2013, Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses, PLoS ONE, 8, e62924, 10.1371/journal.pone.0062924
Li, 1996, The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10, Cancer Immunol Immunother, 43, 213, 10.1007/s002620050324
Pechhold, 1997, Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts, J Immunol, 58, 4921, 10.4049/jimmunol.158.10.4921
Vasaturo, 2013, Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go, Front Immunol, 4, 417, 10.3389/fimmu.2013.00417
Pedicord, 2011, Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance, Proc Natl Acad Sci U S A, 108, 266, 10.1073/pnas.1016791108